Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii

Diagnostic Microbiology and Infectious Disease

Volumn 67, Issue 2, 2010, Pages 191-197

  Pankuch, Glenn A ^a   Seifert, Harald ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Acinetobacter baumannii; Doripenem; Pseudomonas aeruginosa; Time kill synergy

Indexed keywords

AMIKACIN; COLISTIN; DORIPENEM; LEVOFLOXACIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA POLYMORPHISM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 77952743974     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.01.004     Document Type: Article

References (18)

1. Bajaksouzian S., Visalli M.A., Jacobs M.R., Appelbaum P.C. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against Acinetobacters determined by checkerboard and time-kill studies. Antimicrob. Agents Chemother. 1997, 41:1073-1076.
2. Cappelletty D.M., Rybak M.R. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1996, 40:677-683.
3. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition, M07-A8 2009, CLSI, Wayne, PA.
4. Credito K., Lin G., Appelbaum P.C. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus by time-kill methodology. Antimicrob. Agents Chemother. 2007, 51:1504-1507.
5. Eliopoulos G.M., Moellering R.C. Antimicrobial combinations. Antibiotics in laboratory medicine 1991, 432-492. Williams and Wilkins, Baltimore. V. Lorian (Ed.).
6. Falagas M.E., Koletski P.K., Bliziotis I.A. The diversity of definitions of multi-drug resistant (MDR) and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 2006, 55:1619-1629.
7. Fisher R.A. Statistical methods, experimental design and scientific inference 1990, Oxford University Press, Inc, New York.
8. Grundmann H.J., Towner K.J., Dijkshoorn L., Gerner-Smidt P., Maher M., Seifert H., Vaneechoutte M. Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp. J. Clin. Microbiol. 1997, 35:3071-3077.
9. Hilliard J.J., Fernandez J., Melton J.I., Foleno B., Wira E., Lynch A.S., Flamm R.K. Activity of doripenem against Pseudomonas aeruginosa alone and in combination with amikacin, colistin, or levofloxacin. Abstr 49th Intersci Conf Antimicrob Agents Chemother 2009, B-1327. (abstr).
10. Hujer K.M., Hujer A.M., Hulten E.A., Bajaksouzian S., Adams J.M., Donskey C.J., Ecker D.J., Massire C., Eshoo M.W., Sampath R., Thompson J.M., Rather P.N., Craft D.W., Fishbain J.T., Ewell A.J., Jacobs M.R., Paterson D.L., Bonomo R.A. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 2006, 50:4114-4123.
11. Kean S.J. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008, 68:2021-2057.
12. Livermore D.M., Hope R., Brick G., Lillie M., Reynolds R. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J. Antimicrob. Chemother. 2008, 62(Suppl. 2):ii55-ii63. and the BSAC Working Parties on Resistance Surveillance.
13. Manual of Clinical Microbiology. Manual of clinical microbiology 2007, American Society for Microbiology, Washington (DC). 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller (Eds.).
14. Marti S., Sanchez-Céspedes J., Alba V., Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int. J. Antimicrob. Agents 2009, 33:181-182.
15. Pankuch G.A., Lin G., Seifert H., Appelbaum P.C. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother. 2008, 52:333-336.
16. Pillar C.M., Torres M.K., Brown N.P., Shah D., Sahm D.F. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob. Agents Chemother. 2008, 52:4388-4399.
17. Shields R.K., Potoski B.A., Clancy C.J., Adams-Haduch J.M., Doi Y., Kwak E.K., Nguyen M.H. Microbiologic and clinical evidence supporting the combination of doripenem and colistin for the treatment of pan-resistant Acinetobacter. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. 2009, E-1459. (abstr).
18. Vaneechoutte M.L., Dijkshoorn L., Tjernberg I., Elaichouni de Vos A.P., Claeys P.G., Verschraegen G. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J. Clin. Microbiol. 1995, 33:11-15.